Something remarkable is happening in the fight against cancer in America. For the first time since scientists began tracking the disease in a systematic way, the five-year survival rate for all cancers in the United States has reached 70% — up from 49% in the mid-1970s. That number, drawn from the American Cancer Society’s Cancer Statistics 2026 report, represents more than a data point. It represents millions of people alive today who, a generation ago, would not have been.
The driver behind much of that progress is immunotherapy — a class of treatments that works not by poisoning cancer cells directly but by retraining the body’s own immune system to recognize and destroy them. What was once a theoretical frontier in oncology has, over the past two decades, become one of medicine’s defining success stories.
A Half-Century of Progress in a Single Number
The scale of what has changed becomes clear when the numbers are placed in context. From 1991 to 2023, the overall cancer death rate in the United States declined by 34%, translating to an estimated 4.8 million deaths averted. That progress reflects a convergence of forces — reduced smoking rates, advances in early detection, and the accelerating development of targeted and immune-based therapies that have fundamentally altered outcomes for cancers once considered nearly untreatable.
Perhaps no single example illustrates the shift more vividly than metastatic melanoma. Twenty-five years ago, the five-year survival rate for patients diagnosed with advanced melanoma — the deadliest form of skin cancer — was 16%. Today it stands at 35%, a more than twofold improvement driven almost entirely by immune checkpoint inhibitors, drugs that block the proteins cancer uses to hide from the immune system. Antoni Ribas, a professor at UCLA and a member of the Cancer Research Institute’s Scientific Advisory Council, described the significance of that shift plainly: “When we look at metastatic melanoma survival improving from 16% to 35% in just 25 years, we’re witnessing the direct impact of immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 therapies. These are the breakthroughs that the Cancer Research Institute has championed for decades — supporting the fundamental science that made immunotherapies a reality.”
HER2-positive breast cancer tells a similar story. Some patients with metastatic HER2-positive disease are now considered potentially cured — an outcome that would have been unthinkable in earlier decades — following the development of highly targeted therapies that attack specific molecular markers on cancer cells.
Cracking the Code on Previously Untreatable Cancers
The momentum is not slowing. In April 2026, Phase 3 trial results published in the New England Journal of Medicine confirmed the clinical benefit of daraxonrasib, a first-in-class oral targeted therapy for patients with KRAS-mutated pancreatic cancer. The KRAS mutation has historically been considered one of the most challenging targets in oncology — present in the vast majority of pancreatic cancers and, for decades, regarded as effectively “undruggable.” Virginia Cancer Specialists and NEXT Oncology in Northern Virginia served as leading clinical trial sites for the research, reflecting the growing role of community-based cancer centers in advancing the frontier of treatment.
Pancreatic cancer remains one of the most sobering chapters in the current statistics. Its five-year survival rate stands at just 13%, essentially unchanged for years, and the disease accounts for a disproportionate share of cancer mortality relative to its incidence. The daraxonrasib results offer what researchers describe as a potential new standard of care for patients whose disease has progressed after standard chemotherapy — a population with historically limited options.
Science Convenes as the Field Accelerates
This week, the American Association for Cancer Research held its Annual Meeting 2026, a six-day gathering that featured nearly 250 clinical trials, including several described by organizers as practice-changing. Among the presentations was a new physics-based framework called ORIGAMI, developed by researchers at VIB-KU Leuven in Belgium, which analyzes cancer cell shape and volume to detect early signs of treatment resistance in melanoma — enabling researchers to identify interventions that could resensitize resistant cells before the disease progresses. A separate presentation introduced Trace-n-Seq, a novel technique developed at Heidelberg Institute for Stem Cell Technology that allows researchers to map and sequence the neurons infiltrating pancreatic tumors, opening a new window into how the nervous system interacts with cancer and how that interaction might be disrupted therapeutically. Artificial intelligence-assisted diagnostics emerged across the meeting as an accelerating area of investment, with researchers using AI to extract treatment response signals from tumor imaging data that conventional analysis would miss.
Progress Unevenly Distributed
The same report that documents these gains is candid about where progress has stalled and who has been left behind. Colorectal cancer rates are rising 2.9% annually among Americans under 50 even as screening-driven declines continue in older adults. Uterine corpus cancer mortality has climbed for 26 consecutive years. Geographic disparities are stark — cancer death rates range from 122 per 100,000 in Utah and Hawaii to 180 in Kentucky, a 48% gap driven largely by lung cancer and mirroring differences in smoking rates and access to care.
Racial and economic inequities compound the picture. Black men face prostate cancer death rates two to four times higher than other groups. American Indian and Alaska Native populations experience double the mortality rates for kidney, liver, stomach, and cervical cancers compared to other Americans. Asian, Black, and Hispanic patients are less likely to receive recommended genetic testing — a gatekeeping gap that directly limits access to targeted therapies whose efficacy depends on knowing a tumor’s molecular profile.
The report is direct in naming the structural cause: disparate outcomes stem from “less access to high-quality care across the cancer continuum, from prevention to diagnosis and treatment,” not from biological differences between populations.
The Road Still Ahead
The five-year survival rate reaching 70% is a genuine milestone, built on decades of investment in foundational science and clinical research. But the number also means that three in ten Americans diagnosed with cancer today will not reach that threshold — and for some cancers, the odds remain far worse. The question the research community is now pressing is whether the immunotherapy and targeted therapy revolution can be extended to the cancers that have resisted it, distributed equitably to the patients who need it most, and sustained by the research funding that made it possible in the first place.
Disclaimer: This article is intended for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. All statistics and research findings referenced are sourced from publicly available reports and peer-reviewed publications as of the date of this article. Individual cancer diagnoses, treatment options, and outcomes vary significantly depending on cancer type, stage, and patient health profile. Readers should consult a qualified healthcare professional or oncologist regarding any medical condition or treatment decision. Do not disregard or delay seeking professional medical advice based on information contained in this article.
